Full Breakdown
Legislation to Ban Mifepristone: A Push for Federal Action
3/13/2026, 3:34:45 AM
Overview of the Legislation
On March 11, 2026, U.S. Senator Josh Hawley (R-Mo.) introduced the "Safeguarding Women from Chemical Abortion Act," aimed at revoking the Food and Drug Administration's (FDA) approval of mifepristone, a drug commonly used for medication abortions. This legislation seeks to ban the drug's use for terminating pregnancies and create a legal pathway for women who have suffered adverse effects from the drug to sue its manufacturers, primarily Danco Laboratories.
Context and Background
Mifepristone has been a focal point in the abortion debate since its FDA approval in 2000. It accounted for approximately 63% of all abortions in the U.S. in 2023, with over 7.5 million women having used it since its introduction. The drug, when combined with misoprostol, can terminate pregnancies up to 70 days gestation. Hawley argues that the drug has become increasingly unregulated, particularly following the COVID-19 pandemic, which led to eased restrictions on its prescription and distribution.
Key Arguments and Support
Hawley contends that the drug is "inherently dangerous" and prone to abuse, citing a study from the Ethics and Public Policy Center (EPPC) that claims nearly 11% of women experience serious adverse events, such as infection and hemorrhaging, after taking mifepristone. He attributes the rise in complications to the removal of safety protocols under previous administrations, particularly those of Presidents Obama and Biden. The proposed legislation would not only ban the drug for abortion but also allow women harmed by it to seek damages in court.
During a press conference, several women shared personal testimonies about their negative experiences with mifepristone. Elizabeth Gillette recounted her traumatic experience, stating, “I had to decide if I was going to throw my child in the trash or flush my child down the toilet.” Shanyce Thomas, a nursing student, described a severe infection that led to a partial hysterectomy after taking the drug.
Criticism and Opposition
Opponents of Hawley's legislation argue that claims regarding the dangers of mifepristone are politically motivated and not supported by robust scientific evidence. The FDA maintains that mifepristone is safe when used as directed, and studies have consistently shown lower rates of serious complications than those cited by Hawley. Critics, including representatives from the Guttmacher Institute and Planned Parenthood, assert that the drug is backed by decades of data demonstrating its safety and efficacy.
Legislative Landscape and Future Implications
The path forward for Hawley's bill remains uncertain. While it has garnered support from various pro-life organizations, including the Susan B. Anthony Pro-Life America and the Family Research Council, it faces potential opposition from moderate Republicans and the Biden administration, which has indicated a commitment to maintaining access to mifepristone. The legislation could significantly impact abortion access in the U.S., particularly in states with restrictive abortion laws.
Conclusion
Senator Josh Hawley's introduction of the Safeguarding Women from Chemical Abortion Act represents a significant push for federal action against mifepristone, reflecting ongoing divisions within the Republican Party regarding abortion policy. As the debate continues, the implications of this legislation could reshape the landscape of reproductive health in America.
